FDA Regulation of Combination Products

Combination products occupy a distinctive and often contested space in FDA oversight — products that blend drug, device, and biologic components into a single article or co-packaged system. This page covers how FDA defines and classifies combination products, the regulatory mechanisms governing their approval pathways, the scenarios where combination product rules apply, and the boundaries that determine which center takes lead jurisdiction. Understanding these rules is essential for manufacturers navigating approval timelines, labeling requirements, and postmarket obligations that can draw from more than one regulatory framework simultaneously.

Definition and scope

A combination product, as defined under 21 U.S.C. § 353(g) and elaborated in 21 C.F.R. Part 3, is any product comprising two or more regulated components — drug/device, biologic/device, drug/biologic, or drug/device/biologic — that are physically, chemically, or otherwise combined or mixed and produced as a single entity, co-packaged together, or separately packaged but labeled for use only together.

FDA's Office of Combination Products (OCP), established by the Medical Device User Fee and Modernization Act of 2002 (Public Law 107-250), serves as the administrative body responsible for jurisdictional assignments and intercenter coordination. OCP does not itself approve products — it routes them to the appropriate FDA center and resolves disputes when centers disagree.

The four combination product types recognized under 21 C.F.R. § 3.2(e) are:

1. Single-entity combination products — two or more regulated components physically, chemically, or otherwise combined into one article (e.g., a drug-eluting stent).
2. Co-packaged combination products — two or more separate products packaged together in a single container (e.g., a prefilled syringe co-packaged with an auto-injector device).
3. Cross-labeled combination products — separately packaged products labeled for use only with each other, where each component is subject to separate regulatory review.
4. Investigational combination products — products undergoing clinical investigation under an IND or IDE where the combined nature affects the regulatory approach.

The FDA medical device classification framework intersects directly with combination product determinations when a device component's classification influences which center assumes jurisdiction.

How it works

The primary jurisdictional mechanism is the Request for Designation (RFD) process, governed by 21 C.F.R. Part 3, Subpart B. A sponsor submits an RFD to OCP, which has 60 days to issue a jurisdictional assignment. OCP assigns the product to the FDA center with primary mode of action (PMOA) over the product.

PMOA determination follows a specific hierarchy:

1. Identify each component's mode of action.
2. Determine which single mode of action provides the most important therapeutic effect.
3. Assign the product to the center with regulatory oversight of that mode of action.

If PMOA cannot be determined with reasonable certainty — a documented regulatory edge case — OCP defaults to the center with the most expertise relevant to the product's safety and effectiveness questions (21 C.F.R. § 3.4(b)).

Inter-center agreements (ICAs) formalize how the lead center coordinates with the other affected centers. For example, a product assigned to the Center for Drug Evaluation and Research (CDER) that contains a significant device component will involve the Center for Devices and Radiological Health (CDRH) under an ICA. These agreements specify which Good Manufacturing Practice (GMP) regulations apply — 21 C.F.R. Parts 210/211 for drug components, 21 C.F.R. Part 820 (Quality System Regulation) for device components.

The FDA 510(k) clearance process and the FDA premarket approval (PMA) pathway can each serve as the device component's approval mechanism within a combination product submission, depending on device classification.

Common scenarios

Three product categories account for the majority of combination product submissions to OCP:

Drug-device combinations represent the largest category by volume. Examples include prefilled autoinjectors (drug + delivery device), drug-coated orthopedic implants, and topical drug products integrated with a transdermal patch system. CDER typically holds lead jurisdiction when the drug component drives therapeutic effect; CDRH leads when the device component is primary.

Biologic-device combinations include products such as cellular therapy delivered via a specialized catheter, or a vaccine administered through a proprietary needle-free injection system. The Center for Biologics Evaluation and Research (CBER) typically holds jurisdiction for cellular, tissue, and gene therapy products paired with delivery devices.

Drug-biologic combinations — less common but procedurally complex — include products where a biologic modifier (such as an antibody) is chemically conjugated to a small-molecule drug. Antibody-drug conjugates (ADCs) are the most prominent example; CDER has led jurisdiction for most ADC approvals, with CBER input on the biologic component.

Decision boundaries

The PMOA standard is the central decision boundary, but several threshold questions arise before PMOA analysis can proceed:

• Is the product actually a combination product? Single-component products used incidentally with another regulated product are not automatically combination products. A standard syringe used to inject a marketed drug is a device regulated on its own, not a combination product.
• Is the combination product investigational or marketed? Investigational products require coordination between IND and IDE frameworks before PMOA assignment fully governs submission strategy.
• Which GMP framework governs manufacturing? FDA guidance published in January 2017 — Current Good Manufacturing Practice Requirements for Combination Products (21 C.F.R. Part 4) — clarifies that manufacturers must comply with the GMP requirements of the lead center, with specific provisions for demonstrating compliance with the secondary center's GMP standards when both are implicated.

A critical contrast exists between constituent part versus combination product classification. A drug delivered by a device already on the market under separate approval may still form a combination product if the labeling creates a dependency — meaning the drug label specifies that device as the required delivery mechanism. In that scenario, both the drug and the device fall under combination product jurisdiction for the combined system, even if each component holds independent approval.

The FDA drug approval process and FDA biologics license application frameworks each contain provisions for combination product submissions, but the OCP assignment — not the sponsor's preference — determines which application type governs the combined product's primary path to market.

For broader context on how FDA structures its oversight authority across product categories, the FDA centers and offices resource maps the jurisdictional boundaries among CDER, CDRH, and CBER. A full overview of FDA's regulatory scope is available at fdaauthority.com.